The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Long-Term Clinical Improvement in MPTP-Lesioned Primates after Gene Therapy with AAV-hAADC
Open accessAbstract
Dopamine, the major neurotransmitter depleted in Parkinson disease, can be synthesized and regulated in vivo with a combination of intrastriatal AAV-hAADC gene therapy and administration of the dopamine precursor l-Dopa. When tested in MPTP-lesioned monkeys, this approach resulted in long-term improvement in clinical rating scores, significantly lowered l-Dopa requirements, and a reduction in l-Dopa-induced side effects. Positron emission tomography with [(18)F]FMT confirmed persistent AADC activity, demonstrating for the first time that infusion of AAV vector into primate brain results in at least 6 years of transgene expression. AAV-hAADC restores the ability of the striatum to convert l-Dopa into dopamine efficiently. Introduction of this therapy into the clinic holds promise for Parkinson patients experiencing the motor complications that result from escalating l-Dopa requirements against a background of disease progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data
Patlak, C. S., Blasberg, R. G., & Fenstermacher, J. D. (1983) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1983.1 · Cited by 3,567
Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K., & Seitelberger, F. (1973) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(73)90175-5 · Cited by 2,651
Patlak, C. S., & Blasberg, R. G. (1985) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1985.87 · Cited by 1,673
Samii, A., Nutt, J. G., & Ransom, B. R. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16305-8 · Cited by 1,265
SUCCESS AND PROBLEMS OF LONG-TERM LEVODOPA THERAPY IN PARKINSON'S DISEASE
Marsden, C. D., & Parkes, J. D. (1977) · The Lancet · doi:10.1016/s0140-6736(77)91146-1 · Cited by 587
Gibb, W. R., & Lees, A. J. (1991) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.54.5.388 · Cited by 574
Adeno-associated virus vectors can be efficiently produced without helper virus
Matsushita, T., Elliger, S., Elliger, C., Podsakoff, G., Villarreal, L., Kurtzman, G., Iwaki, Y., & Colosi, P. (1998) · Gene Therapy · doi:10.1038/sj.gt.3300680 · Cited by 500
Bankiewicz, K. S., Eberling, J. L., Kohutnicka, M., Jagust, W., Pivirotto, P., Bringas, J., Cunningham, J., Budinger, T. F., & Harvey-White, J. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7408 · Cited by 406
Self-citationThe neurochemistry of Parkinson's disease: effect of L-dopa therapy.
Lloyd, K. G., Davidson, L., & Hornykiewicz, O. (1975) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)30363-0 · Cited by 396
AGID, Y., JAVOY, F., & GLOWINSKI, J. (1973) · Nature New Biology · doi:10.1038/newbio245150a0 · Cited by 366
Cited by
The scientific and clinical basis for the treatment of Parkinson disease (2009)
Olanow, C. W., Stern, M. B., & Sethi, K. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a1d44c · Cited by 908
Marks, W. J., Bartus, R. T., Siffert, J., Davis, C. S., Lozano, A., Boulis, N., Vitek, J., Stacy, M., Turner, D., Verhagen, L., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70254-4 · Cited by 684
Marks, W. J., Ostrem, J. L., Verhagen, L., Starr, P. A., Larson, P. S., Bakay, R. A., Taylor, R., Cahn-Weiner, D. A., Stoessl, A. J., Olanow, C. W., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70065-6 · Cited by 596
Delivery technologies for genome editing
Yin, H., Kauffman, K. J., & Anderson, D. G. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.280 · Cited by 597
The AAV Vector Toolkit: Poised at the Clinical Crossroads
Asokan, A., Schaffer, D. V., & Jude Samulski, R. (2012) · Molecular Therapy · doi:10.1038/mt.2011.287 · Cited by 465
Safety and tolerability of putaminal AADC gene therapy for Parkinson disease
Christine, C. W., Starr, P. A., Larson, P. S., Eberling, J. L., Jagust, W. J., Hawkins, R. A., VanBrocklin, H. F., Wright, J. F., Bankiewicz, K. S., & Aminoff, M. J. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c29356 · Cited by 445
Self-citationResults from a phase I safety trial of hAADC gene therapy for Parkinson disease
Eberling, J. L., Jagust, W. J., Christine, C. W., Starr, P., Larson, P., Bankiewicz, K. S., & Aminoff, M. J. (2008) · Neurology · doi:10.1212/01.wnl.0000312381.29287.ff · Cited by 370
Self-citationTherapeutic AAV Gene Transfer to the Nervous System: A Clinical Reality
Hudry, E., & Vandenberghe, L. H. (2019) · Neuron · doi:10.1016/j.neuron.2019.02.017 · Cited by 369
A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson’s disease
Muramatsu, S.-I., Fujimoto, K.-I., Kato, S., Mizukami, H., Asari, S., Ikeguchi, K., Kawakami, T., Urabe, M., Kume, A., Sato, T., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.135 · Cited by 344
Gene therapy: Comprehensive overview and therapeutic applications
Sayed, N., Allawadhi, P., Khurana, A., Singh, V., Navik, U., Pasumarthi, S. K., Khurana, I., Banothu, A. K., Weiskirchen, R., & Bharani, K. K. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120375 · Cited by 337
Clinical gene therapy using recombinant adeno-associated virus vectors
Mueller, C., & Flotte, T. R. (2008) · Gene Therapy · doi:10.1038/gt.2008.68 · Cited by 313
Long-Term Evaluation of a Phase 1 Study of AADC Gene Therapy for Parkinson's Disease
Mittermeyer, G., Christine, C. W., Rosenbluth, K. H., Baker, S. L., Starr, P., Larson, P., Kaplan, P. L., Forsayeth, J., Aminoff, M. J., & Bankiewicz, K. S. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.220 · Cited by 298
Self-citationNerve Growth Factor Gene Therapy: Activation of Neuronal Responses in Alzheimer Disease
Tuszynski, M. H., Yang, J. H., Barba, D., U, H.-S., Bakay, R. A. E., Pay, M. M., Masliah, E., Conner, J. M., Kobalka, P., Roy, S., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.1807 · Cited by 287
Kordower, J. H., Herzog, C. D., Dass, B., Bakay, R. A. E., Stansell, J., Gasmi, M., & Bartus, R. T. (2006) · Annals of Neurology · doi:10.1002/ana.21032 · Cited by 252
Gene Therapy for Aromatic l -Amino Acid Decarboxylase Deficiency
Hwu, W.-L., Muramatsu, S.-I., Tseng, S.-H., Tzen, K.-Y., Lee, N.-C., Chien, Y.-H., Snyder, R. O., Byrne, B. J., Tai, C.-H., & Wu, R.-M. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003640 · Cited by 246
Gene Therapy for Neurodegenerative Diseases
Sudhakar, V., & Richardson, R. M. (2019) · Neurotherapeutics · doi:10.1007/s13311-018-00694-0 · Cited by 212
Dopamine Gene Therapy for Parkinson’s Disease in a Nonhuman Primate Without Associated Dyskinesia
Jarraya, B., Boulet, S., Scott Ralph, G., Jan, C., Bonvento, G., Azzouz, M., Miskin, J. E., Shin, M., Delzescaux, T., Drouot, X., et al. (2009) · Science Translational Medicine · doi:10.1126/scitranslmed.3000130 · Cited by 186
Christine, C. W., Bankiewicz, K. S., Van Laar, A. D., Richardson, R. M., Ravina, B., Kells, A. P., Boot, B., Martin, A. J., Nutt, J., Thompson, M. E., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25450 · Cited by 167
Self-citationTailoring the AAV vector capsid for gene therapy
Vandenberghe, L. H., Wilson, J. M., & Gao, G. (2009) · Gene Therapy · doi:10.1038/gt.2008.170 · Cited by 155
Lawlor, P. A., Bland, R. J., Mouravlev, A., Young, D., & During, M. J. (2009) · Molecular Therapy · doi:10.1038/mt.2009.170 · Cited by 161
Eight Years of Clinical Improvement in MPTP-Lesioned Primates After Gene Therapy With AAV2-hAADC
Hadaczek, P., Eberling, J. L., Pivirotto, P., Bringas, J., Forsayeth, J., & Bankiewicz, K. S. (2010) · Molecular Therapy · doi:10.1038/mt.2010.106 · Cited by 158
Self-citationGene therapy improves motor and mental function of aromatic l-amino acid decarboxylase deficiency
Kojima, K., Nakajima, T., Taga, N., Miyauchi, A., Kato, M., Matsumoto, A., Ikeda, T., Nakamura, K., Kubota, T., Mizukami, H., et al. (2019) · Brain · doi:10.1093/brain/awy331 · Cited by 139
Reimsnider, S., Manfredsson, F. P., Muzyczka, N., & Mandel, R. J. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300227 · Cited by 125
Hadaczek, P., Forsayeth, J., Mirek, H., Munson, K., Bringas, J., Pivirotto, P., L McBride, J., Davidson, B. L., & Bankiewicz, K. S. (2009) · Human Gene Therapy · doi:10.1089/hum.2008.151 · Cited by 90
Self-citationFechner, H., Sipo, I., Westermann, D., Pinkert, S., Wang, X., Suckau, L., Kurreck, J., Zeichhardt, H., Müller, O., Vetter, R., et al. (2008) · Journal of Molecular Medicine · doi:10.1007/s00109-008-0363-x · Cited by 79
San Sebastian, W., Richardson, R. M., Kells, A. P., Lamarre, C., Bringas, J., Pivirotto, P., Salegio, E. A., DeArmond, S. J., Forsayeth, J., & Bankiewicz, K. S. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.162 · Cited by 48
Self-citationPeden, C. S., Manfredsson, F. P., Reimsnider, S. K., Poirier, A. E., Burger, C., Muzyczka, N., & Mandel, R. J. (2009) · Molecular Therapy · doi:10.1038/mt.2008.284 · Cited by 44
“There was no effect of readministration on striatal GFP+-transduced cells regardless of order of administration [Figure 9a, F(5,20) = 1.”
BackgroundPhysical positioning markedly enhances brain transduction after intrathecal AAV9 infusion
Castle, M. J., Cheng, Y., Asokan, A., & Tuszynski, M. H. (2018) · Science Advances · doi:10.1126/sciadv.aau9859 · Cited by 41
Promising therapeutic agents for the treatment of Parkinson’s disease
Majláth, Z., Török, N., Toldi, J., & Vécsei, L. (2016) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1164687 · Cited by 7
Metadata
- Authors
- Bankiewicz, K. S., Forsayeth, J., Eberling, J. L., Sanchez-Pernaute, R., Pivirotto, P., Bringas, J., Herscovitch, P., Carson, R. E., Eckelman, W., Reutter, B., & Cunningham, J.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2006-10
- Volume
- 14
- Issue
- 4
- Pages
- 564-570
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2095401453
- Cited by
- 282
- References
- 30
- FWCI
- 13.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.